Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

Avadel Pharma

Venator Materials

Here's what you need to know about trading penny stocks on April 26th The post Hot Penny Stocks to Buy Today? 3 For Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Today? 3 For Your Watchlist

PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock split, to be effective 5:00 p.m. on Tuesday, April 26, 2022. The Company's common stock will open for trading on the Nasdaq Market on Wednesday, April 27, 2022 on a split-adjusted basis under the current trading symbol "AGRX." The reverse stock split was approved by Agile's stockholders on April 21, 2022 and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Agile Therapeutics Announces 1-For-40 Reverse Stock Split

Brickell Biotech Inc

IT Tech Packaging Inc

Palatin Technologies

Popular Reddit penny stocks to watch under $1. The post Best Penny Stocks Today?

Best Penny Stocks Today? 4 To Buy For Under $1 According To Reddit

29% increase in Twirla cycles 27% increase in total prescriptions (TRx) of Twirla

Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®

Antares Pharma

Kaleido Biosciences Inc

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes

Histogen

Qualigen Therapeutics

Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today

PRINCETON, N.J., April 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the receipt of $4.7 million in net proceeds from the sale of tax benefits pursuant to the Company's participation in the New Jersey Economic Development Authority (NJEDA) Net Operating Loss (NOL) program under the New Jersey Economic Recovery Act of 2020.

Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program

The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022

Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)

Agile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics.

Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy

Partners with Award-Winning Director Maya Albanese

Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z

Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q4 2021 Results - Earnings Call Transcript

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates

Twirla Demand Grows with Cycles Dispensed and Total Prescriptions (TRx) Up 35% and 33% Respectively in Fourth Quarter 2021 vs Third Quarter 2021

Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update

PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor to sell 2,425 shares of Series A convertible preferred stock and 2,425 shares of Series B convertible preferred stock and Series A warrants to purchase up to an aggregate of 24,250,000 shares of common stock and Series B warrants to purchase up to an aggregate of 24,250,000 shares of common stock. Each share of Series A and Series B preferred stock has a stated value of $1,000 per share and a conversion price of $0.20 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 24,250,000 shares of common stock. The Series A warrants have an exercise price of $0.26 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The Series B warrants have an exercise price of $0.26 per share, will become exercisable six months following the date of issuance, and will expire one and one-half years following the initial exercise date. Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is $4.85 million.

Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering

PRINCETON, N.J., March 11, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will participate in two upcoming investor conferences, including a live panel discussion on drug development in Women's Health.

Agile Therapeutics to Participate in Upcoming March Investor Events

Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET

Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022

PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports women's access to U.S. Food and Drug Administration (FDA) approved contraceptive products. Additionally, on January 11, 2022, the Health Resources and Services Administration (HRSA) updated the Women's Preventative Services Guidelines including contraception services.

Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost

PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a new alliance with Afaxys Pharma, LLC to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal system.

Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET.

Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022.

Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences

Gran Tierra Energy

Matinas BioPharma Hlds

Looking for cheap penny stocks to buy? Here are 4 to watch trading below $1 right now.

Penny Stocks To Buy For Under $1 & What To Watch Right Now

Adamis Pharmaceuticals

Borqs Technologies

Check these Under $1 penny stocks out for your watchlist The post Top Penny Stocks For Your Under $1 List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks For Your Under $1 List Right Now

After trading down from $2.86/share to $.75/share so far this year, Agile's share price is reflecting worse-case scenario. Despite the market sell-off, Agile's business is actually ramping up.

Agile Therapeutics: Worst Is Over

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2021 Results - Earnings Call Transcript

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 5.26% and -13.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Agile Therapeutics Stock (AGRX)